Current asthma management – Best practice in 2023

shutterstock_2124211214 - image for home page

GINA guidelines recommend as-needed budesonide/formoterol as the only treatment for the majority of patients with mild asthma at steps 1 and 2

Learning objectives

  • An understanding of which patients are at risk of severe asthma exacerbations
  • An awareness of the dangers associated with the regular use and overuse of short-acting β-agonist reliever therapy
  • Familiarity with the clinical evidence of benefit when using the single maintenance and reliever therapy (SMART) approach for the management of asthma
  • An awareness of current biologic therapies for the treatment of severe asthma.

Webinar held on 10 August 2023

ATTENTIONKindly note that if you attended the live webinar, you have already received 1 CPD point and will not be permitted to receive additional points for the report. Should this occur, the HPCSA will only record 1 CPD point from the live webinar, invalidating any additional CPD points from the report. Please note deNovo Medica ensures uploading of your CPD points to the HPCSA: please don't upload these yourself.

To access this module, please register or login: